News

Treating refractory and metastatic lung cancer


 

AT THE ASCO ANNUAL MEETING 2013

CHICAGO Dr. Roy Herbst of Yale University discusses early results for MPDL3280A, a new PD-L1 antibody for the treatment of non-small cell lung cancer; he also gives his take on other exciting lung cancer data being presented at the annual meeting of the American Society of Clinical Oncology.

Recommended Reading

Feds abandon fight for graphic cigarette labels
MDedge Family Medicine
Genetics contribute to smoking habits of adolescents, adults
MDedge Family Medicine
Groups seek to curb tobacco use in cancer patients
MDedge Family Medicine
Lung cancer rates highest in West Virginia
MDedge Family Medicine
Androgen deprivation decreases lung tumors in men with prostate cancer
MDedge Family Medicine
Marijuana habit not linked to lung cancer
MDedge Family Medicine
Cardiorespiratory fitness predicts cancer risk, outcomes in men
MDedge Family Medicine
Ultralow-dose CT bests X-Ray for lung cancer follow-up, but is it enough?
MDedge Family Medicine
Real-world NLST results show CT scans find more early-stage lung cancers
MDedge Family Medicine
CDC urges doctors to help patients quit smoking
MDedge Family Medicine